Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/29/19
End: 03/02/22
Due: 03/02/23
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
Phase: N/A
Priority: Normal
Start: 04/30/25
End: 05/31/29
Due: 05/31/30
Phase: N/A
Priority: Normal
Start: 05/09/17
End: 11/22/18
Due: 11/22/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Evaluate Eribulin ORA in Subjects With Solid Tumors | NCT04013217 | Health Hope Pharma | user2@example.com | None | 2019-07-29 | 2022-03-02 | 2023-03-02 | - | - | 2025-07-14 |
| Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | NCT06835400 | Health Hope Pharma | user2@example.com | None | 2025-04-30 | 2029-05-31 | 2030-05-31 | - | - | 2025-07-14 |
| A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients | NCT03165955 | Health Hope Pharma | user2@example.com | None | 2017-05-09 | 2018-11-22 | 2019-11-22 | - | - | 2025-07-14 |